Latent Labs has introduced Latent-X2, an advanced AI platform that creates drug-like biologics on the first attempt. This technology aims to cut down the lengthy and costly process of developing new medicines by generating promising molecules without multiple rounds of testing. The company also added Stefan Oschmann, ex-CEO of Merck KGaA, to its strategic advisory










